|
Background
Androgen receptor activity, mediated by androgens like dihydrotestosterone (DHT), is a key driver of prostate cancer (PCa). Although hormonal therapy remains the cornerstone of PCatreatment, patient responses are highly variable, and it remains difficult to reliably predict who will benefit. Developing predictive biomarkers and accessible...
|